替考拉宁治疗肺癌合并肺部感染临床观察  

Clinical observation of teicoplanin on treatment of lung cancer with pulmonary infection

作　　者：葛晖[1] 金普乐[1] 王敏[1] 秦文文[1] 蒋怡芳[1] 

机构地区：[1]河北医科大学第四医院呼吸科,河北石家庄050011

出　　处：《中华医院感染学杂志》2011年第9期1887-1888,共2页Chinese Journal of Nosocomiology

摘　　要：目的观察替考拉宁治疗肺癌合并肺部感染患者的临床疗效和安全性。方法对32例确诊为肺癌同时合并肺部感染的患者,根据细菌学检查结果或经验性应用替考拉宁治疗,疗程7-14 d,对其疗效、细菌清除率及不良反应发生率进行统计学分析。结果替考拉宁治疗肺癌合并肺部感染,有效率为84.37%,细菌清除率为88.89%,不良反应发生率为6.25%。结论替考拉宁治疗肺癌合并肺部革兰阳性菌感染疗效确切,安全性高。OBJECTIVE To evaluate the efficacy and safety of teicoplanin on treatment of pulmonary infection in patients with lung cancer.METHODS A total of 32 lung cancer patients with pulmonary infection were treated by teicoplanin for 7-14 days.The efficacy,bacterial clearance and side effects were valued.RESULTS The total response was 84.37%,the bacterial clearance was 88.89% and side effect rate was 6.25%.CONCLUSION Teicoplanin is effective and safe for lung cancer patients with Gram-positive cocci pulmonary infection.

关 键 词：替考拉宁 肺癌 肺部感染 革兰阳性球菌 

分 类 号：R978.1[医药卫生—药品]